The purpose of the study is to determine skin irritation and sensitization potential of a topical test article following repeated application. The results demonstrated no signs of irritation or sensitization in any of the test subjects throughout the study period. The mean irritation index was 0.00, indicating the complete absence of adverse dermatological responses.

These findings confirm that the After-Sun Hydrogel Facial Mask is safe for topical use, supporting the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing” “clinically tested” and “safe for sensitive skin.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR), and SkinScience Analytics (SSA) standard operating procedures. All personnel involved in the conduct of this study have completed Human Subjects Protection and ICH GCP Training.

The purpose of the study was to determine the potential of the test material to elicit dermal irritation and/or induce sensitization following repeated patch applications. The results demonstrated that Daily Barrier Cream did not show evidence of irritation or sensitization in any of the test subjects throughout the study period. No adverse events were reported, and all completed subjects exhibited dermal scores of “0” throughout the course of the study.

These findings confirm that Daily Barrier Cream is safe for topical use, supporting the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing,” “clinically tested,” “gentle for sensitive skin,”and “safe for sensitive skin.”

The purpose of the study was to determine the potential of the test material to elicit dermal irritation and/or induce sensitization following repeated patch applications. The results demonstrated that Daily Barrier Cream did not show evidence of irritation or sensitization in any of the test subjects throughout the study period. No adverse events were reported, and all completed subjects exhibited dermal scores of “0” throughout the course of the study.

These findings confirm that Daily Barrier Cream is safe for topical use, supporting the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing,” “clinically tested,” and “safe for sensitive skin.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR)

Pediatric Safety In-Use and Consumer Perception Evaluation

The purpose of the study was to determine the dermal irritation potential and consumer perception of the test material when used in a pediatric population. The results demonstrated that Daily Barrier Cream did not show evidence of irritation or adverse effects in pediatric subjects ages 1 month to 5 years throughout the study period. No adverse events were reported during the study, and the product elicited statistically favorable consumer perception results across all evaluated questions.

These findings confirm that Daily Barrier Cream is gentle for daily pediatric use, supporting the product claims “pediatrician tested,” “non-irritating,” and “clinically tested.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR)

EpiOcular™ Eye Irritation Test (EIT)

The purpose of the study was to evaluate the ocular irritation potential of the test material using the EpiOcular™ Human Cell Construct test method. The results demonstrated that Daily Barrier Cream did not require classification or labeling for eye irritation or serious eye damage under the conditions of the study. The mean tissue viability was 96.48%, indicating excellent ocular compatibility and no irritation potential.

These findings confirm that Daily Barrier Cream is safe for use around the eye area, supporting the product claims “ophthalmologist tested,” “gentle around eyes,” and “non-irritating.”

The study was conducted in accordance with OECD Test Guideline 492 for identifying chemicals not requiring classification and labeling for eye irritation or serious eye damage.

Clinical Moisturization Efficacy Study

The purpose of the study was to evaluate the moisturization efficacy of the test material using instrumental Corneometer measurements. The results demonstrated that Daily Barrier Cream improved skin hydration immediately after application and maintained moisturization through 72 hours post-application under the conditions of the study.

These findings confirm that Daily Barrier Cream provides long-lasting hydration and moisturization benefits, supporting the product claims “clinically tested,” “long-lasting hydration,” and “moisturizing.”

The purpose of the study was to determine the potential of the test material to elicit dermal irritation and/or induce sensitization following repeated patch applications. The results demonstrated that Daily Face & Body Lotion did not show evidence of provoking dermal irritation or eliciting sensitization (contact allergy). Throughout the study, no evidence of irritation or sensitization was observed, and no adverse events were reported.

Based on the conditions of this study, Daily Face & Body Lotion was found to be non-irritating and non-sensitizing. These findings support the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing,” “clinically tested,” “gentle for sensitive skin,” and “safe for sensitive skin.”

The trial was conducted in accordance with International Council on Harmonisation Good Clinical Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR), and SkinScience Analytics standard operating procedures to ensure subject safety, data integrity, and reliability of results.

Pediatric Safety In-Use and Consumer Perception Evaluation

The purpose of the study was to determine the dermal irritation potential and consumer perception of the test material when used in a pediatric population. The results demonstrated that Daily Face & Body Lotion did not show evidence of irritation or adverse effects in pediatric subjects ages 1 month to 5 years throughout the study period. No adverse events were reported during the study, and the product elicited statistically favorable consumer perception results across all evaluated questions.

These findings confirm that Daily Face & Body Lotion is gentle for daily pediatric use, supporting the product claims “pediatrician tested,” “non-irritating,” and “clinically tested.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP) and applicable United States (US) Code of Federal Regulations (CFR).

EpiOcular™ Eye Irritation Test (OECD TG 492)

The purpose of this study was to evaluate the ocular irritation potential of the test material using the validated EpiOcular™ Human Cell Construct in accordance with OECD Test Guideline 492. The results demonstrated that Daily Face & Body Lotion was classified as GHS No Category, indicating that the product does not require classification or labeling for eye irritation or serious eye damage under the conditions of the study. The test material achieved a mean tissue viability of 99.09%, which is well above the 60% threshold established for a No Category classification.

These findings support the product's mildness profile and are consistent with claims such as "gentle around eyes," "non-irritating," and "ophthalmologist tested" when used in conjunction with appropriate product safety substantiation. The study was conducted using the EpiOcular™ Eye Irritation Test, a validated in vitro assay designed to identify products that do not require classification for ocular irritation by measuring tissue viability following exposure to the test material.

The purpose of the study is to determine skin irritation and sensitization potential of a topical test article following repeated application. The results demonstrated no signs of irritation or sensitization in any of the test subjects throughout the study period. The mean irritation index was 0.00, indicating the complete absence of adverse dermatological responses.

These findings confirm that the Face & Body Crayon is safe for topical use, supporting the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing” “clinically tested” and “safe for sensitive skin.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR), and SkinScience Analytics (SSA) standard operating procedures. All personnel involved in the conduct of this study have completed Human Subjects Protection and ICH GCP Training.

The purpose of the study was to determine the potential of the test material to elicit dermal irritation and/or induce sensitization following repeated patch applications. The results demonstrated that Foaming Face & Body Wash did not demonstrate a potential for eliciting dermal irritation or inducing sensitization. Throughout the study, subjects exhibited dermal scores of “0,” indicating no visible skin reactions, and no adverse events were reported.

Based on the conditions of this study, Foaming Face & Body Wash was found to be non-irritating and non-sensitizing. These findings support the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing,” “clinically tested,”  “gentle for sensitive skin,”and “safe for sensitive skin.”

The study was conducted in accordance with International Council for Harmonisation Good Clinical Practice (ICH GCP) standards and applicable clinical testing procedures to ensure subject safety, data integrity, and reliability of results.

Pediatric Safety In-Use and Consumer Perception Evaluation

The purpose of the study was to determine the dermal irritation potential and consumer perception of the test material when used in a pediatric population. The results demonstrated that Foaming Face Wash did not show evidence of irritation or adverse effects in pediatric subjects ages 1 month to 5 years throughout the study period. No adverse events were reported during the study, and the product elicited statistically favorable consumer perception results across all evaluated questions.

These findings confirm that Foaming Face Wash is gentle for daily pediatric use, supporting the product claims “pediatrician tested,” “non-irritating,” and “clinically tested.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP) and applicable United States (US) Code of Federal Regulations (CFR).

EpiOcular™ Ocular Irritation Screening Assay

The purpose of this study was to evaluate the ocular irritation potential of the test material using the EpiOcular™ Human Cell Construct. The results demonstrated that Foaming Face & Body Wash was classified as a Non/Minimal Irritant under the conditions of the study. The test material, evaluated at a 10% dilution, achieved an ET50 value of 185.7 minutes, indicating a low potential for ocular irritation and excellent compatibility with the EpiOcular™ tissue model.

These findings support the product's mildness profile and are consistent with claims such as "gentle around eyes," "non-irritating," and "ophthalmologist tested" when used in conjunction with appropriate product safety substantiation. The study was conducted using a validated in vitro EpiOcular™ Human Cell Construct assay designed to assess ocular irritation potential through measurement of tissue viability following exposure to the test material.

Assessment of a Test Article for Eye Irritation Potential by Ocular Instillation

Ocular safety and potential irritancy are critical factors in assessing the suitability of cosmetic and personal care products for use around the eyes. Ocular instillation of a test product allows for a controlled evaluation of its impact on the delicate ocular tissues. By conducting this study with a diluted form of the test product, we aim to simulate real-life scenarios where products may encounter the eyes in a diluted or unintentional manner. This evaluation will provide valuable insights into the product's safety profile, aiding in formulating guidelines and recommendations for its safe usage. The ocular cul-de-sac is a highly sensitive area, especially in infants, making it susceptible to irritation and discomfort. Baby products, such as shampoos or lotions, can inadvertently encounter the eyes during routine use. Therefore, evaluating the ocular irritancy potential of such products, particularly in a diluted form, is essential to guarantee their gentle nature and adherence to "no tears" claims.

The purpose of the study is to determine skin irritation and sensitization potential of a topical test article following repeated application. The results demonstrated no signs of irritation or sensitization in any of the test subjects throughout the study period. The mean irritation index was 0.00, indicating the complete absence of adverse dermatological responses.

These findings confirm that the Facial Wipes is safe for topical use, supporting the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing,” “clinically tested” and “safe for sensitive skin.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR), and SkinScience Analytics (SSA) standard operating procedures. All personnel involved in the conduct of this study have completed Human Subjects Protection and ICH GCP Training.

Assessment of a Test Article for Eye Irritation Potential by EpiOcular™ Eye Irritation Test (EIT)

The purpose of the study was to evaluate the ocular irritation potential of the test article using the EpiOcular™ Human Cell Construct in accordance with OECD Test Guideline 492. The results demonstrated that the test article, Full Face & Eye Wipes, did not exhibit ocular irritation potential under the conditions of this study. The mean tissue viability was 92.32%, which is above the 60% threshold required for classification as a non-irritant.

These findings confirm that the Full Face & Eye Wipes do not require classification or labeling for eye irritation (GHS No Category), supporting the product claims “Safe for Eyes.”  

The trial is cruelty free and was conducted in accordance with OECD Test Guideline 492: Reconstructed Human Cornea-like Epithelium (RhCE) test method for identifying chemicals not requiring classification and labeling for eye irritation or serious eye damage. No deviations from the study protocol were reported during the conduct of the study.

Assessment of a Test Article for Eye Irritation Potential by Ocular Instillation

Ocular safety and potential irritancy are critical factors in assessing the suitability
of cosmetic and personal care products for use around the eyes. Ocular instillation of a test product allows for a controlled evaluation of its impact on the delicate ocular tissues. By conducting this study with a diluted form of the test product, we aim to simulate real-life scenarios where products may encounter the eyes in a diluted or unintentional manner. This evaluation will provide valuable insights into the product's safety profile, aiding in formulating guidelines and recommendations for its safe usage. The ocular cul-de-sac is a highly sensitive area, especially in infants, making it susceptible to irritation and discomfort. Baby products, such as shampoos or lotions, can inadvertently encounter the eyes during routine use. Therefore, evaluating the ocular irritancy potential of such products, particularly in a diluted form, is essential to guarantee their gentle nature and adherence to "no tears" claims.

The purpose of the study is to determine skin irritation and sensitization potential of a topical test article following repeated application. The results demonstrated no signs of irritation or sensitization in any of the test subjects throughout the study period. The mean irritation index was 0.00, indicating the complete absence of adverse dermatological responses.

These findings confirm that the Gentle (Everyday) Facial Sheet Mask is safe for topical use, supporting the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing” “clinically tested” and “safe for sensitive skin.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR), and SkinScience Analytics (SSA) standard operating procedures. All personnel involved in the conduct of this study have completed Human Subjects Protection and ICH GCP Training.

The purpose of the study is to determine skin irritation and sensitization potential of a topical test article following repeated application. The results demonstrated no signs of irritation or sensitization in any of the test subjects throughout the study period. The mean irritation index was 0.00, indicating the complete absence of adverse dermatological responses.

These findings confirm that the Hydrating Hydrogel Facial Mask is safe for topical use, supporting the product claims “dermatologist tested,” “non-irritating,” “non-sensitizing” “clinically tested” and “safe for sensitive skin.”

The trial was conducted in accordance with International Council on Harmonization Good Clinical Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (CFR), and SkinScience Analytics (SSA) standard operating procedures. All personnel involved in the conduct of this study have completed Human Subjects Protection and ICH GCP Training.